|
10 Nov 2021 |
Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2
|
|
05 Nov 2021 |
Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years
|
|
04 Nov 2021 |
Uvax-2129, a Recombinant Protein Nanoparticle Vaccine, Uvax Bio’s Answer to COVID-19, Shows Great Promise Against Variants of Concern
|
|
01 Nov 2021 |
Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medicines Agency
|
|
30 Oct 2021 |
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
|
|
29 Oct 2021 |
First patient recruited into Alzinova's phase 1b clinical study with the oligomer-specific ALZ-101 vaccine against Alzheimer's disease
|
|
28 Oct 2021 |
Meissa Announces Positive Preliminary Clinical Data on Safety and Immunogenicity of Intranasal COVID-19 Vaccine
|
|
27 Oct 2021 |
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
|
|
27 Oct 2021 |
Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
|
|
27 Oct 2021 |
Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial
|
|
27 Oct 2021 |
Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study
|
|
27 Oct 2021 |
Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of Its mRNA Cytomegalovirus (CMV) Vaccine
|
|
25 Oct 2021 |
Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid Tumors
|
|
25 Oct 2021 |
Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age
|
|
21 Oct 2021 |
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
|
|
21 Oct 2021 |
Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
|
|
21 Oct 2021 |
Daiichi Sankyo Announces Development Progress of mRNA COVID-19 Vaccine in Japan
|
|
21 Oct 2021 |
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
|
|
20 Oct 2021 |
COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy
|
|
18 Oct 2021 |
Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
|
|
16 Oct 2021 |
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
|
|
13 Oct 2021 |
Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
|
|
13 Oct 2021 |
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
|
|
13 Oct 2021 |
First Patient Dosed With PVSRIPO in Istari Oncology’s LUMINOS-103 Phase 1/2 Bladder Cancer Sub-Study
|
|
13 Oct 2021 |
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
|
